Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06541444 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety and Efficacy of NK520 to Treat Relapsed/Refractory Acute Myeloid Leukemia

StatusTerminated
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status changed: Unknown → Terminated Sponsor's reason: poor accrual Show 5 more changesShow less
    • Final enrollment: 2 participants (planned 9)
    • Primary completion date changed from estimate of Jun 1, 2026 to Jun 1, 2025
    • Eligibility criteria expanded, about 41 words
    • Site details revised
    • Study description expanded, about 2 words
  2. Changed Registry marked status Unknown; last known: Recruiting
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will evaluate the safety and efficacy of NK520 in the treatment of relapsed/refractory acute myeloid leukemia. NK520 will be administered by intravenous injection. The safety and efficacy of this treatment will be evaluated.
Trial Details
NCT Number NCT06541444
Lead Sponsor Base Therapeutics (Shanghai) Co., Ltd.
Collaborators: Shanghai Pudong Hospital
Conditions
(from sponsor)		 Relapsed/Refractory Acute Myeloid Leukemia
Related terms Leukemia, Myeloid, Acute
Enrollment 2 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov